Lakefront Biotherapeutics (LKFT) Cash from Operations (2016 - 2026)
Lakefront Biotherapeutics (LKFT) reported Cash from Operations of 110766587.45 for Q1 2026, down 144.96% year-over-year from 246372121.32 in Q1 2025, and down 269.07% quarter-over-quarter from 30012533.94 in Q4 2025.
Lakefront Biotherapeutics (LKFT) Cash from Operations (2016 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 11 years of Cash from Operations data on file, last reported at 110766587.45 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 110766587.45, down 144.96% year-over-year; the trailing twelve-month figure through Mar 2026 was 186031724.72 (up 21.75% YoY), and the FY2025 annual result was 299689987.12, up 12.37% from the prior year.
- Cash from Operations slipped to 110766587.45 in Q1 2026 per LKFT's latest filing, from 30012533.94 in the prior quarter.
- Over five years, Cash from Operations peaked at 34195.05 in Q4 2024 and troughed at 183503731.62 in Q4 2022.
- A 5-year average of 81754853.28 and a median of 69550146.07 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations surged 99.93% in 2024, then tumbled 87668.64% in 2025.
- A 5-year view of Cash from Operations shows it stood at 183503731.62 in 2022, then surged by 74.85% to 46145986.76 in 2023, then surged by 99.93% to 34195.05 in 2024, then plunged by 87668.64% to 30012533.94 in 2025, then slumped by 269.07% to 110766587.45 in 2026.
- Business Quant data shows LKFT's Cash from Operations at 110766587.45 in Q1 2026, 30012533.94 in Q4 2025, and 45218408.29 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | -110.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -110.77 Mn |
| Mar 31, 2026 | -110.77 Mn |
| Dec 31, 2025 | -30.01 Mn |
| Dec 31, 2025 | -30.01 Mn |
| Mar 31, 2025 | -45.22 Mn |
| Mar 31, 2025 | -45.22 Mn |
| Dec 31, 2024 | -34,195.05 |
| Dec 31, 2024 | -34,195.05 |
| Mar 31, 2024 | -146.35 Mn |
| Mar 31, 2024 | -146.35 Mn |
| Dec 31, 2023 | -46.15 Mn |
| Dec 31, 2023 | -46.15 Mn |
| Mar 31, 2023 | -104.22 Mn |
| Mar 31, 2023 | -104.22 Mn |
| Dec 31, 2022 | -183.50 Mn |
| Dec 31, 2022 | -183.50 Mn |
| Mar 31, 2022 | -69.55 Mn |
| Mar 31, 2022 | -69.55 Mn |
| Jun 30, 2021 | -98.66 Mn |
| Jun 30, 2021 | -98.66 Mn |